利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.017 秒)

    Composition for treating diabetes or diabesity comprising oxyntomodulin analog
    1.
    发明授权
    Composition for treating diabetes or diabesity comprising oxyntomodulin analog 有权

    公开(公告)号：US10550168B2

    公开(公告)日：2020-02-04

    申请号：US15960205

    申请日：2018-04-23

    申请人： HANMI PHARM. CO., LTD.

    发明人： Jin Sun Kim ,  Dae Jin Kim ,  Sang Hyun Lee ,  Sung Youb Jung ,  Se Chang Kwon

    IPC分类号： A61K38/22 ,  A61K38/26 ,  C07K14/575 ,  C07K14/605 ,  C07K16/00 ,  C07K16/30 ,  A61K47/64

    摘要： Disclosed are a composition for preventing or treating diabetes, disbesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

    COMPOSITION FOR TREATING HYPERLIPIDEMIA COMPRISING OXYNTOMODULIN DERIVATIVE
    4.
    发明申请
    COMPOSITION FOR TREATING HYPERLIPIDEMIA COMPRISING OXYNTOMODULIN DERIVATIVE 审中-公开
    用于治疗包含氧自由基衍生物的高磷脂酰胆碱的组合物

    公开(公告)号：US20150182593A1

    公开(公告)日：2015-07-02

    申请号：US14415200

    申请日：2013-07-25

    申请人： HANMI PHARM. CO., LTD.

    发明人： Sung Youb Jung ,  Jin-Sun Kim ,  Myung Hyun Jang ,  Sang Hyun Lee ,  In Young Choi ,  Se Chang Kwon

    IPC分类号： A61K38/26 ,  A61K45/06 ,  C07K14/78 ,  C07K14/76 ,  C07K14/605 ,  A61K47/48

    CPC分类号： A61K38/26 ,  A61K38/22 ,  A61K45/06 ,  A61K47/59 ,  A61K47/593 ,  A61K47/60 ,  A61K47/643 ,  A61K47/6435 ,  A61K47/68 ,  A61K47/6811 ,  C07K14/605 ,  C07K14/76 ,  C07K14/78

    摘要： The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.

    摘要翻译： 本发明涉及用于预防或治疗高脂血症，脂肪肝疾病或动脉硬化的组合物，其包含胃泌酸调节素衍生物作为活性成分。 胃泌酸调节蛋白衍生物与天然胃泌酸调节素相比具有高活化GLP-1受体和胰高血糖素受体的能力，并且具有降低高脂肪饮食增加的血液总胆固醇，低密度胆固醇和甘油三酯水平的作用，并且增加高 密度胆固醇水平和高密度胆固醇/低密度胆固醇比值。 因此，胃泌酸调节蛋白衍生物可以有效地用于治疗高脂血症和相关疾病。